Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TorPharm omeprazole approval

Executive Summary

FDA approves Apotex subsidiary's ANDA for omeprazole (AstraZeneca's Prilosec) Oct. 6. Apotex has not announced a launch date, but it is expected by the trade that the generic will be available in mid-November. Apotex would be the fourth generic on the market, following Schwarz, Mylan and Lek (1"The Pink Sheet" Aug. 25, 2003, p. 10)...

You may also be interested in...

Lek Launches Omeprazole; Third Generic Of Prilosec Enters Market

Novartis' Lek generic division is following Mylan with an "at risk" launch of generic omeprazole

PCPC Exploring Solutions With Chinese Authorities To Facilitate Cruelty-Free Cosmetic Imports

France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts